Main Article Content
Non-responder refers to an individual did not develop their anti HBs, even after administration of a 2 complete series of the HBV vaccine. Due to mutant variants, vaccine failure occurred in numerous reports but the incidence of these mutants were unknown. Primary HBV vaccine series failed for nearly 5% of immunocompetent people. There is no clear vision on nonresponse but certain individuals are at major risk, those with persistent diseases, immunosuppressant medication and genetic predisposition. CD-4 T-helper cells that was obtained from viral peptides played an important role in Human Leukocyte antigen (HLA) along with Major Histocompatibility Complex (MHC) and individuals who failed to respond had defect in T helper cells stimulation or antigen presentation. After administration of a course of vaccine, antibody will be produced against major hydrophilic domain of HBsAg in determinant epitope cluster. As upcoming approaches, antigen dose were increased, alternative vaccination, new adjuvants such as immunostimulatory DNA sequences and accelerating vaccination schedules are followed in practice. Increased dosage vaccines, upgraded immunogenicity, adjuvants, surrogate mechanism, combined vaccines and administration of intradermal vaccines are the relevant approaches for a non-responder. Further studies has to be conducted on HLA alleles that can overcome the obstacles in HBV therapeutics.
Balamurali VR. Sujith KV. Leela A, Karthik Jayaprakash T. Prevalence of non-responders among medical laboratory technicians and staff nurses evaluated for anti hepatitis B surface antigen titre. International Journal of Current Microbiology and Applied Sciences. 2020; 9:4:266–272.
World Health Organization. Guidelines for the Prevention Care and Treatment of Hepatitis B infection; 2015.
Vaccine Non-Responders; 2018. Available:https://www.hepb.org/prevention-and-diagnosis/vaccination/vaccine-non-responders/
Paust Silke, Catherine A Blish, Keith Reeves R. Redefining Memory: Building the Case for Adaptive NK Cells. Journal of Virology. 2017;91:20.
Kleinnijenhuis, Johanneke, Jessica Quintin, Frank Preijers, Leo Ab. Joosten et al. BCG-induced trained immunity in NK Cells: Role for non-specific protection to infection. Clinical Immunology 2014; 155(2):213–19.
Kubes P, Deniset J. Faculty opinions recommendation of neutrophils prime a long-lived effector macrophage phenotype that mediates accelerated helminth expulsion. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature; 2016.
Netea, Mihai G. Training innate immunity: The changing concept of immunological memory in innate host defence. European Journal of Clinical Investigation. 2013; 43(8):881–84.
Klenerman P, Fergusson Jr. T cell memory to viral infections. Encyclopedia of Cell Biology. 2016:567–72. Available:https://doi.org/10.1016/b978-0-12-394447-4.30087-6
Reeves, R Keith, Haiying Li, Stephanie Jost, Eryn Blass, Hualin L, et al. Antigen-specific NK cell memory in rhesus macaques. Nature Immunology. 2015; 16(9):927–32.
Romee, Rizwan, Stephanie E. Schneider, Jeffrey W. Leong, Julie M. Chase, et al. Cytokine activation induces human memory-like NK cells. Blood. 2012; 120(24):4751–60.
Goodier, Martin R, Ana Rodriguez-Galan, Chiara Lusa, Carolyn M. Nielsen, Alansana Darboe, et al. Influenza vaccination generates cytokine-induced memory-like NK cells: Impact of human cytomegalovirus infection. The Journal of Immunology. 2016;197(1):313–25.
Sun, Joseph C, Joshua N. Beilke, Lewis L. Lanier. Erratum: Adaptive immune features of natural killer cells. Nature. 2009; 457(7233):1168–68.
Hyams KC. Risks of chronicity following acute hepatitis B virus infection: A review. Clinical Infectious Diseases. 1995;20(4): 992–1000.
Walayat S. Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine. World Journal of Hepatology. 2015;7(24): 2503.
Zhao J, Li Y, Jin L, Zhang S, Fan R, Sun Y, Wang F. Natural killer cells are characterized by the concomitantly increased interferon-γ and cytotoxicity in acute resolved hepatitis B patients. PLoS ONE. 2012;7(11).
Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. 2009; 58(7):974-982.
Tjwa ET, Oord GW, Hegmans JP, Janssen HL, Woltman AM. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. Journal of Hepatology. 2011;54(2):209-218.
Maini MK, Peppa DNK Cells: A double-edged sword in chronic hepatitis B virus infection. Frontiers in Immunology. 2013; 4.
Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV, Global epidemiology of hepatitis B virus. Journal of Clinical Gastroenterology. 2004;38(10): 158-S168.
Kramvis A, Kew M, François G, Hepatitis B virus genotypes. Vaccine. 2005; 23(19):2409-2423.
Norder H, Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology. 1995;38(1-2):24-34
Beck J, Nassal M, Hepatitis B virus replication. World Journal of Gastroenterology: WJG. 2007;13(1):48.
Apurba Sankar Sastry, Sandhya Bhat. Essentials of medical microbiology. Jaypee Brothers Medical Publishers; 2015.
Sood E, Deb VK, Kumar V, Mahato B, Sharma N. Kumar, et al. Hepatitis B Virus (HBV) DNA quantification by real time PCR. Int J Pharma Res Health Sci. 2018; 6(2):2468-71.
Vaccine Non-Responders; 2018. Available:https://www.hepb.org/prevention-and-diagnosis/vaccination/vaccine-non-responders/
Prevention of hepatitis B virus infection in the United States: Recommendations of the advisory committee on immunization practices. Centers for Disease Control and Prevention; 2018. Available:https://www.cdc.gov/mmwr/volumes/67/rr/rr6701a1.html
JSH guidelines for the management of hepatitis B virus infection. Hepatology Research. 2014;44:1–58.
Marchou B, Excler JL, Bourderioux C, Salaun J, Picot N, Yvonnet B, et al. A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: A multicenter, randomized trial comparing accelerated and classic vaccination schedules. Journal of Infectious Diseases. 1995;172(1):258–60.
Rosman, Alan S, Prithwijit Basu, Kathryn Galvin, Charles S. Lieber. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients. The American Journal of Medicine. 1997; 103(3):217–22.
Domínguez M. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transplantation. 2000;6(4):440–42.
Ballinger AB, Clark Ml. Severe acute hepatitis b infection after vaccination. The Lancet. 1994;3448932:1292.
Yang Shigui, Guo Tian, Yuanxia Cui, Cheng Ding, Min Deng, et al. Factors influencing immunologic response to hepatitis B vaccine in adults. Scientific Reports. 2016;6(1).
Purdy, Michaela. Hepatitis B virus S gene escape mutants. Asian Journal of Transfusion Science. 2007;1(2):62.
Hsu HY. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in taiwan. Gut. 2004;53(10):1499–1503.
Sticchi Laura, Patrizia Caligiuri, Roberto Cacciani, Cristiano Alicino, Bianca Bruzzone. Epidemiology of HBV S-Gene mutants in the Liguria Region, Italy. Human Vaccines & Immunotherapeutics. 2013;9(3):568–71.
Bian T, Yan H, Shen L, Wang F, Zhang S, Cao Y, et al. Change in hepatitis B virus large surface antigen variant prevalence 13 years after implementation of a universal vaccination program in China. Journal of Virology 2013;87(22):12196–206.
Godkin, Andrew, Miles Davenport, Adrian V.s. Hill. Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology. 2005; 41(6):1383–90.
Egea E, Iglesias A, Salazar M, Morimoto C, Kruskall MS, Awdeh Z, et al. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. The Journal of Experimental Medicine. 1991; 173(3):531–38.
Derhovanessian Evelyna, Graham Pawelec. Vaccination in the elderly. Microbial Biotechnology. 2011;5(2):226–32. Available:https://doi.org/10.1111/j.1751-7915.2011.00283.x
Heijtink RA. Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers. Vaccine 1994;12(6):532–34.
Overton ET, Sungkanuparph S, Powderly WG, Seyfrieds W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clinical Infectious Diseases. 2005;41(7): 1045–48.
Cruciani Mario, Carlo Mengoli, Giovanni Serpelloni, Andrea Lanza, Maurizio Gomma, Stefano Nardi, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009;27(1):17–22.
Mattos, Angelo Alves De, Eliana Buksztejn Gomes, Cristiane Valle Tovo, Cláudio Osmar Pereira Alexandre, José Oscar Dos Reis Remião. Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C Virus. Arquivos de Gastroenterologia. 2004;41(3):180–84.
Domingo I, Gutierrez JM. Pascasio Acevedo A. Alcalde Vargas A. Ramos Cuadra MT. Ferrer Ríos, et al. Response to vaccination against hepatitis B virus with a schedule of four 40-Μg doses in cirrhotic patients evaluated for liver transplantation: Factors associated with a response.” Transplantation Proceedings. 2012;44(6): 1499–1501.
Daroza, Gerald, Andrea Loewen, Ognjenka Djurdjev, Janet Love, Cathy Kempston, Shelley Burnett, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: Earlier Is better. American Journal of Kidney Diseases. 2003;42(6): 1184–92.
Bonazzi, Patricia R., Telesforo Bacchella, Angela C. Freitas, Karina T. Osaki, Marta H. Lopes, et al. Double-dose hepatitis B vaccination in cirrhotic patients on a liver transplant waiting list. Brazilian Journal of Infectious Diseases. 2008;12(4):306–9.
Wiedmann, Marcus, Uwe G. Liebert, Ute Oesen, Heiner Porst, Manfred Wiese, et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology. 2000;31(1):230–34.
Idilman, Ramazan, Nicola Maria, Alessandra Colantoni, Abdul Nadir, and David H. Thiel. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. The American Journal of Gastroenterology. 2002;97(2):435–39.
Sangaré, Laura, Lisa Manhart, Darin Zehrung, Chia C. Wang. Intradermal hepatitis B vaccination: A systematic review and meta-analysis. Vaccine 2009; 27(12):1777–86.
Katz, Stephen I, Kunihiko Tamaki, David H. Sachs. Epidermal langerhans cells are derived from cells originating in bone marrow. Nature. 1979;282;5736;324–26.
Glenn, Gregory M, Richard T Kenney, Scott A Hammond, Larry R, Ellingsworth. Transcutaneous immunization and immunostimulant strategies. Immunology and Allergy Clinics of North America. 2003; 23(4):787–813.
Rahman, Fareed, Anja Dahmen, Sabine Herzog-Hauff, Wulf O. Böcher, Peter R. Galle, Hanns F. Löhr. Cellular and Humoral Immune Responses Induced by Intradermal or Intramuscular Vaccination with the Major Hepatitis B Surface Antigen. Hepatology. 2000;31(2):521–27.
Dhillon S, Moore C, Li SD, Aziz A, Kakar A, Dosanjh A, et al. Efficacy of high-dose intra-dermal hepatitis B virus vaccine in previous vaccination non-responders with chronic liver disease. Digestive Diseases and Sciences. 2011;57(1):215–20.
Barraclough, Katherine A, Kathryn J. Wiggins, Carmel M. Hawley, Carolyn L. Van Eps, et al. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: A prospective open-label randomized controlled trial in nonresponders to primary vaccination. American Journal of Kidney Diseases. 2009;54(1):95–103.
Hourvitz A, Mosseri R, Solomon A, Yehezkelli Y, Atsmon J, Danon YL, et al. Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing pre-S antigens: A Preliminary Report. Journal of Viral Hepatitis. 1996; 3(1):37–42.
Bertino JS, Tirrell P, Greenberg RN, Keyserling HL, Poland GA, Gump D, et al. A comparative trial of standard or high-dose S subunit recombinant hepatitis b vaccine versus a vaccine containing s subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders. Journal of Infectious Diseases. 1997;175(3): 678–81.
Rendi-Wagner, Pamela, Daniel Shouval, Blaise Genton, Yoav Lurie, Hans Rümke, et al. Comparative immunogenicity of a Pre S/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine. 2006;2 4(15):2781–89.
Zuckerman JN, Sabin C, Craig FM, Williams A, Zuckerman AJ. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: Randomised double blind dose-response study. Bmj. 1997;314(7077):329–29.
Cooper Curtis David Mackie. Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: A review of HEPLISAV™ safety and efficacy. Expert Review of Vaccines. 2011;10(4): 417–27.
Akbar, Sheikh Mohammad Fazle, Shiyi Chen, Mamun Al-Mahtab, Masanori Abe, Yoichi Hiasa, et al. Strong and multi-antigen specific immunity by hepatitis b core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus. Antiviral Research. 2012;96(1):59–64.
Buchmann Pascale, Claudia Dembek, Larissa Kuklick, Clemens Jäger, Raindy Tedjokusumo, et al. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) Transgenic Mice. Vaccine. 2013;31(8): 1197–1203.
Cardell Kristina, Britt Åkerlind, Matti Sällberg, Aril Frydén. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. The Journal of Infectious Diseases. 2008; 198(3):299–304.
Leroux-Roels, Geert, Edwige Haelterman, Cathy Maes, Jack Levy, Fien De Boever, et al. Randomized trial of the immunogenicity and safety of the hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine. Clinical and Vaccine Immunology. 2011; 18(9):1510–18.